Genprex completes tech transfer for gene therapy to manufacturing

By The Science Advisory Board staff writers

December 8, 2020 -- Genprex said that it has completed the technology transfer of the manufacturing process for its Reqorsa lead immunogene therapy candidate to commercial contract development and manufacturing organizations.

The manufacturing technology was transferred from a cancer research institution where Reqorsa was discovered and had previously been manufactured. It has now been manufactured at commercial scale in a current good manufacturing practices-compliant facility for the first time, according to Genprex.

Reqorsa is comprised of a tumor suppressor candidate 2 (TUSC2) plasmid DNA that's encapsulated in nonviral nanoparticles that are administered intravenously and designed to target tumor cells.

The firm said it believes production and process improvements will result in a scalable, reproducible, and stable drug product suitable for storage, shipment, and patient use. In addition, Genprex also believes it's on track to complete manufacturing of clinical-grade Reqorsa to supply the company's upcoming Acclaim-1 and Acclaim-2 clinical trials. These trials, which will combine Reqorsa with, respectively, AstraZeneca's Tagrisso and Merck's Keytruda drugs, are expected to begin in the first half of 2021.

NIH awards $2.59M for diabetes gene therapy
Gene therapy technology developer Genprex said that the U.S. National Institutes of Health (NIH) has awarded a $2.59 million grant to the University...
Genprex expands gene therapy manufacturing
Genprex has expanded its program to manufacture tumor suppressor candidate 2 (TUSC2) with a new manufacturing agreement with partner Aldevron.

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter